Psychiatric medication management for Jupiter — measurement-based, in-person.

For adults in Abacoa, Tequesta, Jupiter Inlet Colony, or Admirals Cove, RECO Integrated Psychiatry sits 32 miles south on I-95 — a 45-minute drive most Jupiter patients complete in a single afternoon block. Initial evaluations run 60 to 90 minutes and produce a documented DSM-5-TR diagnostic formulation, not a symptom checklist. Follow-ups are anchored to PHQ-9, GAD-7, MDQ, ASRS, and Y-BOCS trajectories rather than to whether the patient "feels better today" — the same measurement-based cadence that drives the outcomes literature, and the reason the algorithm keeps moving past the first two SSRIs into augmentation, pharmacogenomics, TMS, and Spravato where they are indicated.

Jupiter sits 32 miles north of RECO Integrated Psychiatry’s Delray Beach office — 45 minutes down I-95 outside of rush hour. For adults in Abacoa, Tequesta, Admirals Cove, or Jonathan’s Landing who have cycled through primary care refills or fifteen-minute telehealth prescribers without seeing the PHQ-9 numbers actually move, that drive buys access to specialist-level outpatient psychiatric medication management — care built around a documented DSM-5-TR formulation, visit-anchored symptom scales, and the full pharmacologic toolkit rather than the SSRI-plus-bupropion loop where most 20-minute visits terminate.

What a real psychiatric evaluation actually covers

The initial visit runs 60 to 90 minutes and produces a documented DSM-5-TR diagnostic formulation, not a symptom checklist forwarded to the pharmacy. History includes every prior psychiatric medication trial with specific doses, durations, and the actual reason for discontinuation — “it didn’t work” gets unpacked into whether the patient reached a therapeutic dose, held it for the expected six to eight weeks, and what side effect or non-response ended the trial. Family psychiatric history, a substance use screen, and trauma history where clinically relevant are documented in the same encounter.

Anyone presenting with “depression” or “anxiety” is screened for bipolarity with the MDQ, for adult ADHD with the ASRS, and for OCD with the Y-BOCS — because unipolar depression treated with an SSRI in an undiagnosed bipolar II patient can precipitate mania, and ADHD masquerading as anxiety is one of the most common diagnostic misses in primary care. Baseline labs — CBC, CMP, TSH, B12, folate, vitamin D — are ordered where indicated to rule out medical contributors before adjusting psychotropics. This is the workup a 15-minute refill visit cannot support.

Measurement-based care and why it changes outcomes

PHQ-9 for depression, GAD-7 for anxiety, MDQ for bipolar screening, ASRS for ADHD, and Y-BOCS for OCD are administered before each visit, scored during the visit, and tracked longitudinally. The evidence on measurement-based care is unambiguous: routine outcome measurement produces meaningfully better remission rates than clinical impression alone, largely because it forces earlier medication adjustments in patients who are stalling rather than genuinely improving.

A PHQ-9 that has moved from 18 to 14 over six weeks looks identical on a “how are you feeling?” question to one that has moved from 18 to 8 — but the treatment implications are opposite. Medication decisions at RECO are anchored to the scale trajectory. If the patient is not on track to remission by the expected timeline, the visit ends with a specific pharmacologic change, not another month of the same dose.

The pharmacologic toolkit beyond the first two SSRIs

First-line pharmacotherapy is well-established and non-controversial — SSRIs and SNRIs (sertraline, escitalopram, venlafaxine, duloxetine) for major depression and anxiety, stimulants and non-stimulants for ADHD, mood stabilizers (lithium, valproate, lamotrigine) and atypical antipsychotics for bipolar disorder, SSRIs paired with an ERP referral for OCD. The value of specialty psychiatry is what happens after first- and second-line trials fail.

That toolkit includes augmentation with aripiprazole, lithium, or T3 thyroid in treatment-resistant depression; switching within and across classes when partial response plateaus; MAOIs where clinically appropriate; buspirone or hydroxyzine for anxiety when benzodiazepines are contraindicated; and pharmacogenomic testing (GeneSight, Genomind) in patients with multiple failed trials or unusual side effect profiles. In genuinely treatment-resistant cases the algorithm escalates to interventional treatment — rTMS delivered at 120% of motor threshold over the left DLPFC, or Spravato (esketamine) under REMS-registered supervision — rather than the third or fourth SSRI switch.

Monitoring: the labs, the metabolic panel, the drug levels

Psychiatric medications carry real monitoring requirements, and the RECO visit cadence is built around them. Lithium requires baseline and periodic TSH, creatinine, and calcium, plus serum levels drawn 12 hours post-dose on a stable regimen — typically quarterly once dose-stable. Atypical antipsychotics (quetiapine, olanzapine, risperidone, aripiprazole) require baseline and at-least-annual metabolic panels: HbA1c, fasting lipids, weight, and blood pressure. Valproate requires baseline LFTs, platelets, and serum valproate levels.

Stimulants require a documented cardiovascular history and blood pressure checked at each visit, with EKG considered where risk factors are present. Lamotrigine requires the slow titration schedule to reduce Stevens-Johnson risk. These are not optional; they are standard of care. The protocol builds them into the visit template so nothing is missed because the patient forgot to ask or the prescriber ran out of time.

What to expect on your first visit

Intake paperwork — demographics, ROIs, and the pre-visit PHQ-9 and GAD-7 — is completed before arrival. Bring photo ID, insurance card, and a current medication list with doses and prescribers. The 60- to 90-minute evaluation is conducted by a board-certified psychiatric provider, not by an intake coordinator. The diagnostic formulation and initial treatment plan are discussed in the same visit; if a prescription is appropriate, it is sent to the pharmacy that afternoon along with any indicated baseline labs.

Follow-up cadence is typically every two to four weeks during titration and every six to twelve weeks once stable. Where indicated, psychotherapy referral is made in parallel — CBT for depression and anxiety, ERP for OCD, EMDR or trauma-focused CBT for PTSD, DBT skills for emotion dysregulation, MI where ambivalence about treatment is prominent. Medication management does not substitute for therapy in conditions where the evidence supports combined treatment.

Insurance and admissions from Jupiter

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Benefits are verified before the initial visit so copay, deductible, and any prior authorization requirements for controlled substances or interventional treatments (TMS, Spravato) are known in advance. Out-of-network patients receive itemized superbills for reimbursement. New-patient evaluations from Jupiter are generally scheduled within one to two weeks, with most Abacoa and Tequesta clients timing appointments outside the I-95 rush windows to keep the round trip under two hours.

Serving residents of: Abacoa, Jupiter Inlet Colony, Tequesta, Admirals Cove, Jonathan's Landing.